Montelukast Sodium Articles

Asthma preventive drugs market led by GlaxoSmithKline's Advair

26 November 2012

FDA approves first generic copies of Merck & Co's Singulair; and Pulmicort Respules

6 August 2012

New Zealand's PHARMAC to fund alternative treatments for asthma, scabies from Merck

31 July 2012

Asthma pill more user-friendly than inhalers - and no less effective

6 May 2011

Merck & Co rises 2.3% as it beats 4th quarter 2009 sales forecast, boosted by Schering-Plough

17 February 2010

One time gain triples Merck & Co’s 3rd quarter 2009 earnings, beating forecasts; EU clears S-P deal

23 October 2009

Merck wins Singulair patent infringement law suit with Teva

20 August 2009

Tentative FDA OK for Mylan's generic Singulair

29 May 2009

Japan stock market week to May 18, 2009

19 May 2009

Merck & Co 1st-qtr profit slumps 57%

21 April 2009

2007 Vioxx settlement sees Merck & Co 2008 profit up, despite lower sales

9 February 2009

US FDA concludes Singulair and other LRAs are not associated with suicide risk

19 January 2009

Merck & Co's 2009 outlook below predictions due to forex effects and restructuring costs

15 December 2008

Merck & Co's 3rd-qtr EPS drops 27% on restructuring; further downsizing to come

3 November 2008

Study finds no suicide link with Merck & Co's Singulair

8 September 2008

Sugammadex gets "not-approvable" FDA letter; S-P working to resolve issues

11 August 2008

Merck & Co income still up despite low sales

28 July 2008

No to Merck & Co/S-P combo allergy drug

5 May 2008

Merck & Co 1Q results saved by AZ payout

28 April 2008

SkyePharma secures Flutiform Japan partner

28 April 2008

FDA investigates suicide link with Singulair

7 April 2008

EMEA's PDCO issues PIP review opinions

4 February 2008

Vioxx costs see Merck & Co swing to $1.6B loss

4 February 2008

Merck & Co's 2008 EPS forecast short of estimates, but predicts stronger sales

10 December 2007

Merck & Co's 3rd-qtr 2007 sales jump 12%

29 October 2007

Singulair reduces child asthma doctor visits

15 October 2007

US FDA accepts for filing NDA for fixed-dose loratadine/montelukast combo pill

3 September 2007

Merck & Co's 2nd-qtr 2007 EPS jumps 12%

30 July 2007

Merck & Co's 1st-qtr income climbs 12%

30 April 2007

US FDA approves Merck & Co's Singulair in EIB

30 April 2007

Merck & Co's 3rd-qtr income down 38% to $904.6 million on flat sales and higher costs

30 October 2006

Merck and Co's 2nd-qtr 2006 net income reaches $1.4B thanks to Zocor and Singulair

31 July 2006

Merck & Co launches complaint over generic copies of its Fosamax in France

10 July 2006

MHRA expands UK label for MSD's Singulair

12 June 2006

Merck & Co sees 1st-qtr net income of $1.52B

1 May 2006

Merck & Co beats forecasts; profit up 2%

6 February 2006

Positive data on Merck & Co's Singulair

11 July 2005

Vioxx loss drags on Merck & Co results

22 April 2005

New use for Singulair

7 March 2005

Merck & Co, hit by Vioxx withdrawal, sees 4th-qtr EPS in line with expectations

31 January 2005

Merck & Co's first taste of life after Vioxx; earnings per share to take substantial hit

20 December 2004

Merck & Co launches pediatric Singulair in UK

11 October 2004

Merck & Co 2nd-qtr profit dips 2%

26 July 2004

Merck & Co reports 5% drop in 1st-qtr income

3 May 2004

US FTA future "threatened by Australian anger over pharma provisions"

22 March 2004

Merck & Co 4th-qtr in line with estimates; net income down 23%

2 February 2004

MSD Spain expects to close 2003 with a 10% sales hike, invests in R&D

20 October 2003

Positive new data for Merck & Co's Singulair

13 October 2003

Profits up at Merck & Co on branded sales but still lower than estimates

28 July 2003

Revenues up at Merck & Co on key drug sales, profits hit by increased spending

28 April 2003

Israeli Health Ministry proposes 128 new drugs for 2003 NHI health services basket

20 January 2003

Stock Commentary - New York

13 January 2003

Merck & Co's Singulair OKed for rhinitis

6 January 2003

USA "must not use govt-controlled drug coverage decisions to curb costs:" DHHS

22 July 2002

Millennium drops oral formulation of asthma drug MLN977

22 July 2002

Tokyo pharma stocks - week to May 20

27 May 2002

Leading Japanese drugmakers post strong financials, forecast further growth

27 May 2002

Merck & Co upbeat about its future, as 1st-qtr net income slips 2%

29 April 2002

Ranbaxy gets US OK for generic Ceftin

25 February 2002

Five key products continue to drive Merck & Co sales in 2001

28 January 2002

Update: Merck and Schering-Plough file for approval of cholesterol drug

7 January 2002

Merck, S-P file in USA for cholesterol drug

7 January 2002

Update: Merck points to robust pipeline despite near-term profits warning

13 December 2001

Merck points to robust pipeline despite near-term profits warning

12 December 2001

Japan pharma stocks - week to October 1

3 October 2001

$400M Singapore unit opened by Merck & Co

12 September 2001

GSK claims Advair superior to Singulair

10 September 2001

Stock Commentary - Tokyo

6 September 2001

Banyu launches two Merck drugs in Japan

6 September 2001

Japan pharma stocks, week to Sept 3rd

5 September 2001

Japan pharma stocks in week to August 27

29 August 2001

Five drugs push Merck & Co sales up 25%

23 July 2001

Japan pharma stocks week to July 2, 2001

4 July 2001

Stock Commentary - Tokyo

28 June 2001

Japan pharma stock market, week to June 25

27 June 2001

Merck & Co issues profit warning as Vioxx sales start to slow

25 June 2001

Nu-lotan driving sales at Banyu

8 June 2001

Positive Advair data compared to Singulair/fluticasone

31 May 2001

Japan pharma stock market week to May 21

23 May 2001

Merck & Co's Singulair - a treatment for seasonal allergic rhinitis?

17 May 2001

Aventis says strategy for growth is working at R&D presentation

16 May 2001

Merck & Co buying Rosetta for $620 mill; rumors of a $91 bill bid for S-P

14 May 2001

Singulair cleared for young children in Canada

25 April 2001

Merck & Co sales leap 28%; EPS up 13%

23 April 2001

GSK launches Advair for asthma in USA; major marketing push planned

18 April 2001

Singulair effective as allergy treatment

23 March 2001

New Singulair dose launched in UK

19 February 2001

Five key products push Merck & Co sales up 23% to over $40 billion in 2000

24 January 2001

Schering-Plough to build four new facilities in Singapore for $450 million

11 December 2000

Merck & Co posts stronger-than-expected profits for the third quarter

23 October 2000

Merck & Co posts strong sales growth

25 July 2000

MSDW explores US prescription sales in major therapeutic areas

6 July 2000

Merck & Co and Schering-Plough setting up major research alliances

23 May 2000

Merck & Co's Singulair effective in pediatric activity-induced asthma

11 May 2000

Merck & Co's net income climbs 15% in 1st quarter to $1.5 billion

25 April 2000

Lilly and Ono link up for sivelestat critical care drug

18 April 2000

Banyu aims to be among Japan's top five

21 March 2000

Singulair approved for use in younger children

8 March 2000

Healthy full-year results for many US pharmaceutical companies

27 January 2000

Merck's Singulair shows superiority in exercise-induced asthma

19 January 2000

Showing 1-100 of 142 articles

Go to beginningPreviousNextGo to end